NEW YORK, March 31, 2017 -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of SCYNEXIS, Inc. (NASDAQ:SCYX) who purchased shares (1) pursuant and/or traceable to the Registration Statement and Prospectus issued in connection with the Company’s Initial Public Offering on or about May 2, 2014 and/or (2) between May 2, 2014 and March 2, 2017. You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the District of New Jersey.
In particular complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (i) SCYNEXIS’s lead product SCY-078 posed substantial undisclosed health and safety risks; (ii) consequently, the Company had overstated the drug’s approval prospects and/or commercial viability; and (iii) as a result of the foregoing, SCYNEXIS’s public statements were materially false and misleading at all relevant times.
On March 2, 2017, SCYNEXIS announced that the U.S. Food and Drug Administration “informed the Company to hold the initiation of any new clinical studies with the intravenous (IV) formulation of SCY-078 until the FDA completes a review of all available pre-clinical and clinical data” of the formulation. The hold stems from “three mild-to-moderate thrombotic events in healthy volunteers” receiving the formulation.
Shareholders have until May 8, 2017 to petition the court for lead plaintiff status. Your ability to share in any recovery does not require that you serve as lead plaintiff. You may choose to be an absent class member.
If you suffered a loss during the class period and wish to obtain additional information, please contact Joseph Klein, Esq. by telephone at 212-616-4899 or visit http://www.kleinstocklaw.com/pslra-sa/scynexis-inc.
Joseph Klein, Esq. is an experienced attorney and has also practiced as a Certified Public Accountant. Mr. Klein represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Joseph Klein, Esq. Empire State Building 350 Fifth Avenue 59th floor New York, NY 10118 Telephone: (212) 616-4899 Fax: (347) 558-9665 www.kleinstocklaw.com


U.S. Government Invests $1 Billion in L3Harris Rocket Motor Business to Secure Missile Supply Chain
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market
HSBC Expands UAE Presence With New Asset Management Business and Onshore Funds
Zhipu AI Launches GLM-Image Model Trained on Huawei Chips, Boosting China’s AI Self-Reliance Drive
Rio Tinto–Glencore Talks Spark Pressure on BHP as Copper Fuels Mining Mega Deals
Lynas CEO Amanda Lacaze to Retire After 12 Years as Rare Earths Demand Grows
Trump Considers Starlink to Restore Internet Access in Iran Amid Protests
Netflix Plans All-Cash Bid for Warner Bros Discovery Studios Amid Intense Hollywood Takeover Battle
BlackRock to Cut Around 250 Jobs as CEO Larry Fink Pushes Strategic Shift
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s
Trump Administration Approves Nvidia H200 AI Chip Sales to China Under New Export Rules
Vitol to Ship First U.S. Naphtha Cargo to Venezuela Under New Oil Supply Deal
Alphabet Stock Poised for Growth as Bank of America Sees Strong AI Momentum Into 2026
Anthropic Launches HIPAA-Compliant Healthcare Tools for Claude AI Amid Growing Competition
Starlink Internet Remains Active in Iran Despite Nationwide Blackout
AFT Leaves X Over AI-Generated Images of Minors
BESI Reports Strong Q4-25 Orders Surge Driven by Data Center and Hybrid Bonding Demand 



